Brought to you by 
Alza and XenoPort collaborate on prodrugs
11 Feb 2003
Executive Summary
In a multi-year project, Johnson & Johnson's Alza unit will combine its drug delivery technologies with XenoPort Inc.'s prodrug compounds that take advantage of the body's cellular transport systems.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com